Ovarian Cancer

Maintenance Olaparib Boosted Survival by 1 Year in Relapsed BRCA-Related Ovarian Cancer

By

Leah Lawrence

Publish Date May 22, 2020

Olaparib should be new standard for maintenance in these patients.

Lynparza Plus Bevacizumab Approved for First-Line Maintenance in HRD-Positive Advanced Ovarian Cancer

By

Diana Ernst, RPh

Publish Date May 11, 2020

The FDA has approved Lynparza® for use in combination with bevacizumab as first-line maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer

Role of Olaparib as Maintenance Treatment for Ovarian Cancer: The Evidence to Date

Publish Date January 10, 2020

[OncoTargets and Therapy] In this review, researchers summarize use, indications, and clinical safety and efficacy of olaparib, a PARP inhibitor, in the treatment of ovarian cancer, including in patients with BRCA mutations.

New Research Says There’s No Significant Link Between Talc and Ovarian Cancer, but Some Scientists Push Back Against the Study’s Data and Design

By

Sarah Elizabeth Richards

Publish Date January 10, 2020

Some experts say the talc study’s data limitations weaken its impact in the field.

Fertility-Sparing Surgery Achieves Good Oncologic, Obstetric Outcomes in Younger Women With Early-Stage Nonepithelial Ovarian Cancer

By

Susan Moench, PhD, PA-C

Publish Date January 7, 2020

In this first reported prospective study, researchers compared outcomes of fertility-sparing surgery with radical surgery in women with stage I nonepithelial ovarian cancer.

Ovarian Cancer Clinical Trials

Clinical Trial: Specimen and Data Study for Ovarian Cancer Early Detection and Prevention

Clinical Trial: Prophylactic Salpingectomy With Delayed Oophorectomy

Clinical Trial: Interactive Educational Website for Women With Ovarian Cancer & Caregivers

Clinical Trial: Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status

Clinical Trial: AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer